https://www.selleckchem.com/products/Y-27632.html
This work aims to evaluate the long-term safety of rituximab (RTX) in primary Sjögren's syndrome (pSS) to determine the safety and the efficacy of long-term treatment with B cell depleting therapy in pSS patients with active systemic disease. An historical cohort study, enrolling 35 pSS patients treated with RTX, between 2008 and 2019, in a single Rheumatologic Unit was performed. When patients experienced adverse events, the treatment was suspended, and patients' data were recorded. The included patients were mainly female (91%) with a
Like
Comment
Share
